Goldman Sachs’s HCW Biologics HCWB Stock Holding History

Goldman Sachs’s Portfolio HCWB Stock Details HCWB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-82	Closed	-$63K	–	6550
2021 Q3	$63K	Buy	+82	New	+$86.3K	﹤0.01%	6000

Other funds holding HCWB

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAM

Cresset Asset Management Chicago, Illinois $23.1B AUM 27.04% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

FWM

Focused Wealth Management Newburgh, New York $964M AUM 18.71% 1-Year Est. Return

Goldman Sachs's HCWB Position: Q4 2021 in Review

Goldman Sachs sold out of HCW Biologics (HCWB) in Q4 2021, closing a stake of 82 shares — an estimated $63K sold.

Goldman Sachs first reported a position in HCWB in Q3 2021 and held it in 1 quarter. The position peaked at $63K in Q3 2021. 11 funds tracked by Wall St. Rank hold HCWB as of Q4 2021.

Goldman Sachs reported no remaining HCW Biologics position as of Q4 2021 after selling out during the quarter.
Goldman Sachs sold 82 HCW Biologics shares in Q4 2021, an estimated $63K.
Goldman Sachs first reported a position in HCW Biologics in Q3 2021 and held it in 1 quarter.
Goldman Sachs's HCW Biologics position peaked at $63K in Q3 2021.
11 funds tracked by Wall St. Rank held HCW Biologics as of Q4 2021.

Based on Goldman Sachs's 13F filing for Q4 2021, filed 14 Feb 2022.